Literature DB >> 9890557

Rapid hydrolysis and slow alpha,beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links.

P J Thornalley1, H S Minhas.   

Abstract

The putative protein glycation cross-link cleaving agent N-phenacylthiazolium bromide (PTB) underwent hydrolysis and cyclic hemithioacetal formation under physiological conditions to form two isomeric 2,3-dihydro-4-formyl-2-hydroxy-2-phenyl-1,4-thiazines: at pH 7.4 and 37 degrees, the rate constant k(Hydrolysis) was (2.6+/-0.1) x 10(-4) sec and the chemical half-life was ca. 44 min. The alpha,beta-dicarbonyl cleavage reaction only competed effectively with the hydrolysis when the alpha,beta-dicarbonyl substrate was at nonphysiological high levels. The high concentrations of PTB (10-30 mM) used previously to demonstrate chemical and biochemical activity also lead to acidification of incubation media. The mechanism of action of PTB now requires reappraisal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9890557     DOI: 10.1016/s0006-2952(98)00284-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

Review 1.  Targeting advanced glycation with pharmaceutical agents: where are we now?

Authors:  Danielle J Borg; Josephine M Forbes
Journal:  Glycoconj J       Date:  2016-07-09       Impact factor: 2.916

2.  Cleavage of in vitro and in vivo formed lens protein cross-links by a novel cross-link breaker.

Authors:  Seth Hollenbach; Prajitha Thampi; Tito Viswanathan; Edathara C Abraham
Journal:  Mol Cell Biochem       Date:  2003-01       Impact factor: 3.396

3.  Reversal of chaperone activity loss of glycated alphaA-crystallin by a crosslink breaker.

Authors:  Poppy Datta; Latha Kallur; Edathara C Abraham
Journal:  Mol Cell Biochem       Date:  2008-06-03       Impact factor: 3.396

4.  Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I.

Authors:  E Nobécourt; J Zeng; M J Davies; B E Brown; S Yadav; P J Barter; K-A Rye
Journal:  Diabetologia       Date:  2008-04-24       Impact factor: 10.122

Review 5.  Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.

Authors:  Casper G Schalkwijk; Toshio Miyata
Journal:  Amino Acids       Date:  2010-10-20       Impact factor: 3.520

6.  Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis.

Authors:  A V Mezentsev; S A Bruskin; A G Soboleva; V V Sobolev; E S Piruzian
Journal:  Int J Biomed Sci       Date:  2013-09

Review 7.  Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.

Authors:  Naila Rabbani; Mingzhan Xue; Paul J Thornalley
Journal:  Glycoconj J       Date:  2016-07-12       Impact factor: 2.916

8.  Jakyakgamcho-tang and Its Major Component, Paeonia Lactiflora, Exhibit Potent Anti-glycation Properties.

Authors:  Junghyun Kim; Chan-Sik Kim; Young Sook Kim; Ik Soo Lee; Jin Sook Kim
Journal:  J Exerc Nutrition Biochem       Date:  2016-12-31

Review 9.  The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach.

Authors:  Parveen Salahuddin; Gulam Rabbani; Rizwan Hasan Khan
Journal:  Cell Mol Biol Lett       Date:  2014-08-20       Impact factor: 5.787

Review 10.  Emerging Glycation-Based Therapeutics-Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors.

Authors:  Naila Rabbani; Paul J Thornalley
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.